You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
Drug Formulary
About the Drug Formulary Email Drug Formulary Team

azaCITIDine

( ay-za-SYE-ti-deen )
Funding:
New Drug Funding Program
  • Azacitidine - Acute Myeloid Leukemia (AML)
  • Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)
... Show more tags
Other Name(s): Vidaza® (Celgene)
Appearance: White, milky suspension for injection

Drug Monograph

Nov 2017
Table of Contents
Eligibility Forms
pdf download Azacitidine - Acute Myeloid Leukemia (AML) pdf download Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)

Patient Info Sheet

Apr 2016

What it is used for

  • For treating certain types of blood disorders, such as myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)


You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration